Asia Pac ECM and Index Rebal, Shenton Research

Ke Yan, CFA, FRM

Asia Pac ECM and Index Rebal

Asia Pac IPO & Placement Research, China Biotech

DZT Research

DZT Research is an independent Asia Pacific equity specialist. Our quantitative research covers index rebalancing flows, alongside exchange data analytics accross Asia Pacific. On the equity capital markets side, we focus on Asia Pacific ECM, especially biotech and TMT. Our lead analyst is frequently cited by international media.

Quantitative Analysis

<ul>
<li>We analyse the changes of A-H premium on 162 stocks over the last week. The average A-H premium was 69.1% as of Jan 2nd.</li>
<li>The average A-H premium changed by 1.3ppt week-on-week, led by consumer staples, materials, health care and offset by consumer discretionary.</li>
<li>We highlight weekly changes in A-H premium for Goldwind, Jiangxi Copper, Fudan Microelectronics, Guangzhou Automobile, Zijin Mining, Cmoc.</li>
</ul>


We analyse the changes of A-H premium on 162 stocks over the last week. The average A-H premium was 69.1% as of Jan 2nd.
The average A-H premium changed by 1.3ppt week-on-week, led by consumer staples, materials, health care and offset by consumer discretionary.
We highlight weekly changes in A-H premium for Goldwind, Jiangxi Copper, Fudan Microelectronics, Guangzhou Automobile, Zijin Mining, Cmoc.


A-H Premium Weekly (Jan 2nd): Goldwind, Jiangxi Copper, Fudan Microelectronics, Guangzhou Automobile

HK/China Healthcare Analyst (ex-Fosun Pharma)

Xinyao (Criss) Wang

Equity Capital Markets

IMPACT Therapeutics / Equity Capital Markets

<ul>
<li>Senaparib demonstrated statistically significant and clinically meaningful improvement in PFS in Phase III trial, which is its core competitiveness, but Senaparib is facing challenges in commercialization due to fierce competition.</li>
<li>The potential of IMP1734/IMP9064/IMP7068/IMP1707 depends on clinical success, the approval schedule, final indications layout. In optimistic scenario, a blockbuster drug has the potential to reach peak sales of RMB1-2 billion.</li>
<li>RMB1-2.25 billion could be valuation bottom line, which is below the post-money valuation of RMB3.3 billion after Series D++ Financing. Meanwhile, valuation of IMPACT would be lower than Zai Lab.</li>
</ul>


Senaparib demonstrated statistically significant and clinically meaningful improvement in PFS in Phase III trial, which is its core competitiveness, but Senaparib is facing challenges in commercialization due to fierce competition.
The potential of IMP1734/IMP9064/IMP7068/IMP1707 depends on clinical success, the approval schedule, final indications layout. In optimistic scenario, a blockbuster drug has the potential to reach peak sales of RMB1-2 billion.
RMB1-2.25 billion could be valuation bottom line, which is below the post-money valuation of RMB3.3 billion after Series D++ Financing. Meanwhile, valuation of IMPACT would be lower than Zai Lab.


Pre-IPO IMPACT Therapeutics - Thoughts on the Pipeline, the Concerns and Valuation Outlook

IPOs and Catalysts/Events, Global Equity Research Ltd

Arun George

IPOs and Catalysts/Events

Uncompromised, Independent, Conflict-Free Research

Global Equity Research Ltd

Global Equity Research was started in 2017 by a group of experienced research professionals. It was founded on a passionate belief in the importance and the need for uncompromised, independent, conflict-free research. We aim to provide differentiated and actionable primary and bottom up fundamental research.

Event-Driven

<ul>
<li>Nine months after the offer was announced, <a href="https://www.smartkarma.com/entities/enn-natural-gas-co-ltd" target="_blank" data-smartkarma-citation="entities:16456:1" rel="noopener">ENN Natural Gas (600803 CH)</a> has satisfied the regulatory precondition related to its <a href="https://www.smartkarma.com/entities/enn-energy-holdings-ltd" target="_blank" data-smartkarma-citation="entities:316:1" rel="noopener">ENN Energy (2688 HK)</a> offer. </li>
<li>The remaining precondition is approval from CSRC and HKEx, which are low-risk. The long stop date is 13 March 2026, which may have to be extended.</li>
<li>The appraised offer HK$80.00 value is the key debating point. Based on several methodologies, I estimate a realistic offer value of HK$78.53 (range of HK$71.85 to HK$89.72).</li>
</ul>


Nine months after the offer was announced, ENN Natural Gas (600803 CH) has satisfied the regulatory precondition related to its ENN Energy (2688 HK) offer. 
The remaining precondition is approval from CSRC and HKEx, which are low-risk. The long stop date is 13 March 2026, which may have to be extended.
The appraised offer HK$80.00 value is the key debating point. Based on several methodologies, I estimate a realistic offer value of HK$78.53 (range of HK$71.85 to HK$89.72).


ENN Energy (2688 HK): Regulatory Precondition Satisfied

<ul>
<li>We analyse the changes of A-H premium on 160 stocks over the last week. The average A-H premium was 65.7% as of Dec 19th.</li>
<li>The average A-H premium changed by 2.0ppt week-on-week, led by consumer discretionary, information technology, utilities.</li>
<li>We highlight weekly changes in A-H premium for BankComm, Anjoy Foods, Cosco Shipping Development, Shanghai Electric.</li>
</ul>


We analyse the changes of A-H premium on 160 stocks over the last week. The average A-H premium was 65.7% as of Dec 19th.
The average A-H premium changed by 2.0ppt week-on-week, led by consumer discretionary, information technology, utilities.
We highlight weekly changes in A-H premium for BankComm, Anjoy Foods, Cosco Shipping Development, Shanghai Electric.


A-H Premium Weekly (Dec 19th): BankComm, Anjoy Foods, Cosco Shipping Development, Shanghai Electric

China

Jiangsu Hengrui Pharmaceuticals is a global biopharmaceutical company engaged in the research, development, manufacturing, and commercialization of innovative and high-quality drugs. The company focuses on therapeutic areas including oncology, metabolic and cardiovascular diseases, immunological and respiratory diseases, and neuroscience. It was founded in 1970 and is headquartered in Lianyungang, Jiangsu, China.

Jiangsu Hengrui Pharmaceuticals (1276 HK)

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Jiangsu Hengrui Pharmaceuticals (1276 HK)

A-H Premium Weekly (Jan 2nd): Goldwind, Jiangxi Copper, Fudan Microelectronics, Guangzhou Automobile

We analyzed A-H premium changes in the past week and highlight A-H premium changes for Goldwind, Jiangxi Copper, Fudan Microelectronics, Guangzhou...

Ke Yan, CFA, FRM

Pre-IPO IMPACT Therapeutics - Thoughts on the Pipeline, the Concerns and Valuation Outlook

Senaparib shows promise in improving PFS but face commercialization challenge.Pipeline potential hinges on clinical success/approval...

Xinyao (Criss) Wang

ENN Energy (2688 HK): Regulatory Precondition Satisfied

Nine months in, the regulatory precondition was finally satisfied. Based on several methodologies, I estimate a realistic offer value of HK$78.53...

Arun George

A-H Premium Weekly (Dec 19th): BankComm, Anjoy Foods, Cosco Shipping Development, Shanghai Electric

We analyzed A-H premium changes in the past week and highlight A-H premium changes for BankComm, Anjoy Foods, Cosco Shipping Development, Shanghai...

Ke Yan, CFA, FRM

A-H Premium Weekly (Dec 19th): BankComm, Anjoy Foods, Cosco Shipping Development, Shanghai Electric

We analyzed A-H premium changes in the past week and highlight A-H premium changes for BankComm, Anjoy Foods, Cosco Shipping Development, Shanghai...

Ke Yan, CFA, FRM

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)

A-H Premium Weekly (Jan 2nd): Goldwind, Jiangxi Copper, Fudan Microelectronics, Guangzhou Automobile

We analyzed A-H premium changes in the past week and highlight A-H premium changes for Goldwind, Jiangxi Copper, Fudan Microelectronics, Guangzhou...

Ke Yan, CFA, FRM

Pre-IPO IMPACT Therapeutics - Thoughts on the Pipeline, the Concerns and Valuation Outlook

​Senaparib shows promise in improving PFS but face commercialization challenge.Pipeline potential hinges on clinical success/approval...

Xinyao (Criss) Wang

ENN Energy (2688 HK): Regulatory Precondition Satisfied

Nine months in, the regulatory precondition was finally satisfied. Based on several methodologies, I estimate a realistic offer value of HK$78.53...

Arun George

A-H Premium Weekly (Dec 19th): BankComm, Anjoy Foods, Cosco Shipping Development, Shanghai Electric

We analyzed A-H premium changes in the past week and highlight A-H premium changes for BankComm, Anjoy Foods, Cosco Shipping Development, Shanghai...

Ke Yan, CFA, FRM

A-H Premium Weekly (Dec 19th): BankComm, Anjoy Foods, Cosco Shipping Development, Shanghai Electric

We analyzed A-H premium changes in the past week and highlight A-H premium changes for BankComm, Anjoy Foods, Cosco Shipping Development, Shanghai...

Ke Yan, CFA, FRM

Senaparib shows promise in improving PFS but face commercialization challenge.Pipeline potential hinges on clinical success/approval...